Physiologically based pharmacokinetic modeling to predict complex drug‐drug interactions: a case study of AZD2327 and its metabolite, the competitive and time‐dependent CYP3A inhibitors

In conclusion, this model simulated DDI with less than two‐fold error, indicating that complex clinical DDI associated with multiple mechanisms, pathways, and inhibitors (parent and metabolite) can be predicted using well developed PBPK model. This article is protected by copyright. All rights reserved.
Source: Biopharmaceutics and Drug Disposition - Category: Drugs & Pharmacology Authors: Tags: Original Paper Source Type: research